UCL Discovery
UCL home » Library Services » Electronic resources » UCL Discovery

Tackling amyloidogenesis in Alzheimer's disease with A2V variants of Amyloid-β

Di Fede, G; Catania, M; Maderna, E; Morbin, M; Moda, F; Colombo, L; Rossi, A; ... Tagliavini, F; + view all (2016) Tackling amyloidogenesis in Alzheimer's disease with A2V variants of Amyloid-β. Scientific Reports , 6 , Article 20949. 10.1038/srep20949. Green open access

[thumbnail of Published article] Text (Published article)
Fede_Tackling amyloidogenesis in Alzheimer's disease VoR.pdf - Published version

Download (2MB)
[thumbnail of Supplementary information]
Preview
Text (Supplementary information)
Fede_Tackling amyloidogenesis in Alzheimer's disease Supplementary.pdf - Accepted version

Download (573kB) | Preview

Abstract

We developed a novel therapeutic strategy for Alzheimer’s disease (AD) exploiting the properties of a natural variant of Amyloid-β (Aβ) carrying the A2V substitution, which protects heterozygous carriers from AD by its ability to interact with wild-type Aβ, hindering conformational changes and assembly thereof. As prototypic compound we designed a six-mer mutated peptide (Aβ1-6A2V), linked to the HIV-related TAT protein, which is widely used for brain delivery and cell membrane penetration of drugs. The resulting molecule [Aβ1-6A2VTAT(D)] revealed strong anti-amyloidogenic effects in vitro and protected human neuroblastoma cells from Aβ toxicity. Preclinical studies in AD mouse models showed that short-term treatment with Aβ1-6A2VTAT(D) inhibits Aβ aggregation and cerebral amyloid deposition, but a long treatment schedule unexpectedly increases amyloid burden, although preventing cognitive deterioration. Our data support the view that the AβA2V-based strategy can be successfully used for the development of treatments for AD, as suggested by the natural protection against the disease in human A2V heterozygous carriers. The undesirable outcome of the prolonged treatment with Aβ1-6A2VTAT(D) was likely due to the TAT intrinsic attitude to increase Aβ production, avidly bind amyloid and boost its seeding activity, warning against the use of the TAT carrier in the design of AD therapeutics.

Type: Article
Title: Tackling amyloidogenesis in Alzheimer's disease with A2V variants of Amyloid-β
Open access status: An open access version is available from UCL Discovery
DOI: 10.1038/srep20949
Publisher version: http://dx.doi.org/10.1038/srep20949
Language: English
Additional information: This work is licensed under a Creative Commons Attribution 4.0 International License. The images or other third party material in this article are included in the article’s Creative Commons license, unless indicated otherwise in the credit line; if the material is not included under the Creative Commons license, users will need to obtain permission from the license holder to reproduce the material. To view a copy of this license, visit http://creativecommons.org/licenses/by/4.0/
UCL classification: UCL
UCL > Provost and Vice Provost Offices > UCL BEAMS
UCL > Provost and Vice Provost Offices > UCL BEAMS > Faculty of Engineering Science
UCL > Provost and Vice Provost Offices > UCL BEAMS > Faculty of Engineering Science > Dept of Chemical Engineering
URI: https://discovery.ucl.ac.uk/id/eprint/1532142
Downloads since deposit
98Downloads
Download activity - last month
Download activity - last 12 months
Downloads by country - last 12 months

Archive Staff Only

View Item View Item